Cue Biopharma (CUE) CEO Lin Shao-Lee Sells $305K of Stock

Lin Shao-Lee, the CEO of Cue Biopharma, Inc. (CUE), sold 11,087 shares on October 12, 2026, for about $305,490. This sale comes as the stock trades below its moving averages and has been under pressure recently.

Inside Lin Shao-Lee's Trade

Shao-Lee's sale involved 11,087 shares at a price of $27.55 each. This transaction is not planned, and it occurred on the same day as other insider sales by company executives. The sale reflects ongoing activity among insiders at Cue Biopharma.

Other Institutional Activity in Cue Biopharma

Several institutional investors have also adjusted their positions in Cue Biopharma. Bleichroeder LP increased its stake by 143,381 shares, bringing its total to 370,682 shares worth about $6.19 million. Driehaus Capital Management, LLC added 146,072 shares, ending with 292,144 shares valued at approximately $4.88 million. Vanguard Capital Management LLC boosted its holdings by 79,785 shares, totaling 161,700 shares worth about $2.70 million. Ikarian Capital, LLC grew its position by 52,182 shares, now holding 104,364 shares valued at roughly $1.74 million. Tetragon Partners GP Ltd. also added 46,910 shares, bringing its total to 93,819 shares worth about $1.57 million.

Cue Biopharma, Inc. Stock Down 3.7%

The stock of Cue Biopharma recently traded around $17.98 as of October 16, 2026. This price is significantly below its 50-day moving average of $27.56 and its 200-day average of $20.70. Furthermore, it is about 60.5% below its 52-week high of $45.50 but remains above its 52-week low of $4.98, reflecting considerable volatility in its stock price.

Recent Earnings

In its latest financial report, Cue Biopharma had trailing twelve-month revenue of approximately $37.7 million. The company has not yet achieved profitability, reporting an earnings per share (EPS) of -$29.59.

Insider Buying and Selling at Cue Biopharma, Inc.

On the same day as Shao-Lee's sale, other insiders also sold shares. Meluzio Michael Vincent, the VP and Principal Accounting Officer, sold 1,144 shares for about $32,089. Ray Sumita, the Chief Legal Compliance Officer, sold 1,844 shares valued at approximately $51,724. Another officer, Sumita J.D. Ray, sold the same number of shares for a similar value.

Analysts Set New Price Targets

On September 18, 2026, B. Riley Securities initiated coverage on Cue Biopharma with a "Buy" rating and set a price target of $83.00. The consensus among analysts has a mean price target of $88.00 based on three opinions, indicating a favorable outlook compared to the current trading price.

About Cue Biopharma

Cue Biopharma, Inc. is a clinical-stage biotechnology company based in Boston, MA. It focuses on developing therapies for immunological disorders, with its lead asset, CUE-221, currently in Phase 2 development for allergic diseases. The company also utilizes its Immuno-STAT platform to target disease-specific T cells without affecting the broader immune system.

Bottom Line

Investors should watch for further insider trading activity and upcoming earnings reports to gauge the company's financial health. Given the recent insider sales and the stock's current pricing, market sentiment may shift as new information becomes available.